Anti-CD123-anti-CD3 bispecific antibody (Janssen Research & Development)

N/A

Report date: 2026/03/19 16:59:43

Base Information

Drug NameAnti-CD123-anti-CD3 bispecific antibody (Janssen Research & Development)
Drug Alias NameAb-178
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitorsT cell surface glycoprotein CD3 inhibitors
TargetsInterleukin-3 receptor subunit alphaT cell surface glycoprotein CD3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Research & Development Llc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A